Abstract
We reported evidence of bradykinin (BK) regeneration from C-terminal extended BK sequences that behave as peptidase-activated B2 receptor (B2R) agonists. Further to these in vitro studies, we carried out in vivo experiments to verify hemodynamic effects of BK analogs exhibiting variable susceptibility toward vascular and blood plasma peptidases. Rats were anesthetized and instrumented to record blood pressure and heart rate responses to bolus intravenous (i.v.) injection of increasing doses of BK, B-9972 (D-Arg-[Hyp(3),Igl(5),Oic(7),Igl(8)]-BK), BK-Arg, BK-His-Leu or BK-Ala-Pro, in the absence or presence of specific inhibitors. In some experiments, pulsed Doppler flow probes measured hindquarter Doppler shift in response to i.v. injections of kinins. BK caused rapid, transient and dose-related hypotensive effects. These effects were potentiated ∼15-fold by the angiotensin converting enzyme (ACE) inhibitor, enalaprilat, but extensively inhibited by icatibant (a B2R antagonist) and not influenced by the Arg-carboxypeptidase (CP) inhibitor (Plummer's inhibitor). The hypotensive responses elicited by the peptidase-resistant B2R agonist, B-9972, were not affected by enalaprilat, but were inhibited by icatibant. The hypotensive resp...Continue Reading
References
Apr 22, 1977·Science·M A OndettiD W Cushman
Jul 9, 1979·Life Sciences·A Nasjletti, K U Malik
Mar 1, 1991·British Journal of Pharmacology·F J HockJ Knolle
Mar 1, 1991·British Journal of Pharmacology·K WirthJ Knolle
Jan 1, 1992·British Journal of Pharmacology·H BachelardT Bennett
Jan 1, 1992·British Journal of Pharmacology·H BachelardT Bennett
Jan 14, 1992·European Journal of Pharmacology·N E RhalebJ Knolle
Jun 1, 1990·Circulation·L LinderT F Lüscher
Apr 1, 1989·British Journal of Pharmacology·P D'Orléans-JusteJ R Vane
Sep 1, 1989·Hypertension·H IshidaO A Carretero
Jan 30, 1981·Biochemical and Biophysical Research Communications·T H Plummer, T J Ryan
Oct 10, 1997·Hypertension·X P YangO A Carretero
Oct 29, 1998·The New England Journal of Medicine·J V GainerN J Brown
Jul 25, 2000·Hypertension·I B SquireJ L Reid
Oct 29, 2000·British Journal of Pharmacology·J F LarrivéeF Marceau
Nov 1, 2000·Circulation·N J BrownD E Vaughan
Feb 28, 2001·Proceedings of the National Academy of Sciences of the United States of America·P MenetonF Alhenc-Gelas
Apr 3, 2001·Circulation Research·S BergayaC M Boulanger
Jun 19, 2001·American Journal of Physiology. Heart and Circulatory Physiology·M CyrA Adam
Dec 31, 2002·European Journal of Pharmacology·Paul ScottJenny Longmore
Feb 5, 2003·Circulation·Mias PretoriusNancy J Brown
Feb 15, 2003·European Journal of Pharmacology·Yuko MutoHidemi Ishii
May 2, 2003·Expert Opinion on Investigational Drugs·Holger Heitsch
Mar 1, 2005·Pharmacological Reviews·L M Fredrik Leeb-LundbergBruce L Zuraw
Apr 30, 2005·FASEB Journal : Official Publication of the Federation of American Societies for Experimental Biology·V Griol-CharhbiliC Richer
May 10, 2005·Peptides·Laimute Taraseviciene-StewartNorbert F Voelkel
Sep 24, 2005·Journal of Pharmacological Sciences·Marie Eve MoreauAlbert Adam
Apr 25, 2007·Proceedings of the National Academy of Sciences of the United States of America·Masao KakokiOliver Smithies
Aug 19, 2007·The Journal of Pharmacology and Experimental Therapeutics·Marie-Thérèse BawolakFrançois Marceau
Oct 10, 2008·Circulation·Lei XiRakesh C Kukreja
Sep 30, 2009·British Journal of Pharmacology·Marie-Thérèse BawolakFrançois Marceau
Feb 27, 2010·American Journal of Hypertension·Maria MarketouHaralambos Gavras
May 11, 2010·Peptides·Gérémy Abdull KoumbadingaFrançois Marceau
Sep 8, 2011·The Journal of Clinical Hypertension·Joseph L Izzo, Matthew R Weir
Apr 18, 2013·The Journal of Pharmacology and Experimental Therapeutics·Louis PotierNadine Bouby
Mar 19, 2014·Frontiers in Pharmacology·Xavier Charest-MorinFrançois Marceau